Inhibition of calcium-dependent regulator-stimulated phosphodiesterase activity by neuroleptic drugs is unrelated to their clinical efficacy.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000201:enzymology; D002069:Butaclamol / Q000494:pharmacology; D002118:Calcium / Q000502:physiology*; D002417:Cattle; D002749:Chlorprothixene / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D005475:Flupenthixol / Q000494:pharmacology; D066298:In Vitro Techniques; D007536:Isomerism; D010726:Phosphodiesterase Inhibitors
D014150:Antipsychotic Agents; D010726:Phosphodiesterase Inhibitors; D002749:Chlorprothixene; D002069:Butaclamol; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D005475:Flupenthixol; D002118:Calcium